Treatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS)
High rates of treatment discontinuation and subsequent restart were observed across all subgroups, implying fluctuating sMRA use. However, heightened cardiovascular risk may decrease the odds of discontinuation.
Authors
- Alain Gay (ORCID: https://orcid.org/0000-0002-0689-7168)
- Vincent J. Willey (ORCID: https://orcid.org/0000-0002-6473-6469)
- Elena Pessina
- Charlie Scott (ORCID: https://orcid.org/0000-0002-2816-4889)
- Nihar R. Desai (ORCID: https://orcid.org/0000-0003-2384-2545)
- Nikolaus G. Oberprieler
- Kerstin Folkerts
- Rakesh K. Singh (ORCID: https://orcid.org/0000-0003-3235-9934)
- Emma Richard
- Chia‐Chen Teng
Institutions
- Clarion University (US)
- Bayer (Norway) (NO)
- Bayer (United States) (US)
- Eli Lilly (United States) (US)
- Yale University (US)
- Bayer (Italy) (IT)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Pragmatic and Observational Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/por.s489791
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer